Here's Why We Think Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Is Well Worth Watching
Here's Why We Think Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.
對於那些熱衷於投資能夠扭轉命運的公司的投機者來說,這是一個很吸引人的點,所以即使是沒有收入、沒有利潤且未能達到預期表現的公司,也能夠找到投資者。但正如彼得·林奇在《華爾街的勝利法則》中所說:“長遠計劃幾乎從未有所收穫。” 虧損的公司一直在與時間賽跑,以達到財務可持續性,因此這些公司的投資者可能承擔了比應承擔的風險更多。
In contrast to all that, many investors prefer to focus on companies like Chengdu Kanghong Pharmaceutical Group (SZSE:002773), which has not only revenues, but also profits. While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.
相比之下,許多投資者更喜歡專注於像成都康弘藥業集團(SZSE:002773)這樣不僅有營收,還有利潤的公司。雖然利潤不是投資時應考慮的唯一指標,但是值得承認的是,能夠持續產生利潤的企業是值得投資的。
How Fast Is Chengdu Kanghong Pharmaceutical Group Growing Its Earnings Per Share?
成都康弘藥業集團的每股收益增速如何?
Over the last three years, Chengdu Kanghong Pharmaceutical Group has grown earnings per share (EPS) at as impressive rate from a relatively low point, resulting in a three year percentage growth rate that isn't particularly indicative of expected future performance. As a result, we'll zoom in on growth over the last year, instead. Chengdu Kanghong Pharmaceutical Group's EPS shot up from CN¥0.96 to CN¥1.24; a result that's bound to keep shareholders happy. That's a fantastic gain of 29%.
在過去的三年裏,康弘藥業每股收益以驚人的速度增長,但增長率並不特別能預示未來業績。因此,我們更注重去年的增長。康弘藥業的每股收益從0.96元人民幣升至1.24元人民幣,這個結果肯定會讓股東們高興。這是一個驚人的增長29%。
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. Chengdu Kanghong Pharmaceutical Group shareholders can take confidence from the fact that EBIT margins are up from 25% to 29%, and revenue is growing. Both of which are great metrics to check off for potential growth.
公司的營收增長是可持續增長的重要指標,加上高的利息稅前利潤率,這是企業在市場上保持競爭優勢的重要方式。康弘藥業的股東可以信懇智能,利潤率從25%上升至29%,而且營業收入在增長。這兩個指標都是潛在增長的重要指標。
You can take a look at the company's revenue and earnings growth trend, in the chart below. To see the actual numbers, click on the chart.
您可以查看下圖中企業的營收和收益增長趨勢。要查看實際數字,請單擊圖表。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240725/0-f5b0ecc30812cf6c9a4ffd69743ba650-0-b4f11c7c52c4173f1a000fc7fbc84ebc.png/big)
While it's always good to see growing profits, you should always remember that a weak balance sheet could come back to bite. So check Chengdu Kanghong Pharmaceutical Group's balance sheet strength, before getting too excited.
雖然看到盈利增長總是好的,你應該記住,一個薄弱的資產負債表會回到咬你的身上。因此,在過度興奮之前,請檢查成都康弘藥業集團的資產負債表情況。
Are Chengdu Kanghong Pharmaceutical Group Insiders Aligned With All Shareholders?
成都康弘藥業集團內部人員與所有股東的利益是否相一致?
Theory would suggest that it's an encouraging sign to see high insider ownership of a company, since it ties company performance directly to the financial success of its management. So those who are interested in Chengdu Kanghong Pharmaceutical Group will be delighted to know that insiders have shown their belief, holding a large proportion of the company's shares. In fact, they own 39% of the shares, making insiders a very influential shareholder group. Shareholders and speculators should be reassured by this kind of alignment, as it suggests the business will be run for the benefit of shareholders. CN¥7.1b This is an incredible endorsement from them.
理論上,看到公司高內部人員持股應該是一個令人鼓舞的跡象,因爲它將公司的績效與其管理層的財務成功直接聯繫起來。因此,對於成都康弘藥業集團感興趣的人來說,內部人員已經表明了他們的信念,持有公司的大部分股份。實際上,他們擁有39%的股份,從而成爲一個非常有影響力的股東群體。股東和投機者應該對這種態度感到放心,因爲這意味着該企業將爲股東的利益而運作。這是他們的一份 incredible 的認可。
Is Chengdu Kanghong Pharmaceutical Group Worth Keeping An Eye On?
成都康弘藥業集團值得關注嗎?
You can't deny that Chengdu Kanghong Pharmaceutical Group has grown its earnings per share at a very impressive rate. That's attractive. With EPS growth rates like that, it's hardly surprising to see company higher-ups place confidence in the company through continuing to hold a significant investment. Fast growth and confident insiders should be enough to warrant further research, so it would seem that it's a good stock to follow. Still, you should learn about the 1 warning sign we've spotted with Chengdu Kanghong Pharmaceutical Group.
康弘藥業的每股收益增長非常驚人,這是非常有吸引力的。隨着這樣的每股收益增長率,公司高層繼續持有大量投資,並對公司持有信懇智能,這是毫不令人驚訝的。快速增長和對公司的信任足以表明股票非常值得關注。但我們還是應該學習一下康弘藥業的1個警示信號。
While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in CN with promising growth potential and insider confidence.
雖然不選取增長收益和缺少內部人買入的股票可能會產生效果,但是對於重視這些關鍵指標的投資者,這裏是一份精心挑選的具有巨大增長潛力和內部人信心的CN公司列表。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
請注意,本文討論的內部交易是指在相關司法管轄區中報告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。